Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | B-cell CLL/lymphoma 2 | Starlite/ChEMBL | References |
Homo sapiens | BCL2-like 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | Get druggable targets OG5_139665 | All targets in OG5_139665 |
Echinococcus granulosus | EGFP:Bcl2 fusion protein | Get druggable targets OG5_139665 | All targets in OG5_139665 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | dihydroorotate dehydrogenase (fumarate) | 0.0865 | 1 | 0.5 |
Leishmania major | dihydroorotate dehydrogenase | 0.0865 | 1 | 0.5 |
Schistosoma mansoni | dihydroorotate dehydrogenase | 0.0865 | 1 | 0.5 |
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.0835 | 0 | 0.5 |
Mycobacterium leprae | Probable dihydroorotate dehydrogenase PyrD | 0.0865 | 1 | 0.5 |
Toxoplasma gondii | dihydroorotate dehydrogenase reveal, putative | 0.0865 | 1 | 0.5 |
Plasmodium vivax | dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.0865 | 1 | 0.5 |
Plasmodium falciparum | dihydroorotate dehydrogenase | 0.0865 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydroorotate dehydrogenase 2 | 0.0865 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable dihydroorotate dehydrogenase PyrD | 0.0865 | 1 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.0865 | 1 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase (fumarate), putative | 0.0865 | 1 | 0.5 |
Mycobacterium ulcerans | dihydroorotate dehydrogenase 2 | 0.0865 | 1 | 0.5 |
Echinococcus granulosus | EGFP:Bcl2 fusion protein | 0.0835 | 0 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.0865 | 1 | 0.5 |
Brugia malayi | Dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.0865 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 0.471 uM | Binding affinity to Bcl-XL by fluorescence polarization assay | ChEMBL. | 16451081 |
Ki (binding) | = 0.471 uM | Binding affinity to Bcl-XL by fluorescence polarization assay | ChEMBL. | 16451081 |
Ki (binding) | = 1.98 uM | Binding affinity to Bcl2 by fluorescence polarization assay | ChEMBL. | 16451081 |
Ki (binding) | = 1.98 uM | Binding affinity to Bcl2 by fluorescence polarization assay | ChEMBL. | 16451081 |
Ki (binding) | > 10 uM | Binding affinity to Bcl-XL in 1% human serum by fluorescence polarization assay | ChEMBL. | 16451081 |
Ki (binding) | > 10 uM | Binding affinity to Bcl-XL in 1% human serum by fluorescence polarization assay | ChEMBL. | 16451081 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.